Clinical Trials Logo

Clinical Trial Summary

The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called "enterotyping" analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma. The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma.


Clinical Trial Description

The prevalence of asthma in preschool children is estimated to between 11 and 12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called "enterotypeing" analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma. The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma. The goal of this study is to research a difference between respiratory dysbiosis and severe asthma (i.e. resistant to doses of inhaled corticosteroids less than or equal to 200μg of fluticasone equivalent). DREAM is a exploratory multicentric prospective case-control study. The primary objective is to research a difference between respiratory dysbiosis and severe asthma (i.e. resistant to doses of inhaled corticosteroids less than or equal to 200μg of fluticasone equivalent) in children less than 36 months of age. The secondary objectives are : 1. To compare the bacterial pulmotypes of children under 36 months of age with severe asthma with children with mild or moderate asthma. 2. To look for microbial biomarkers associated with corticosteroid resistance 3. To assess the association between digestive dysbiosis and severe asthma (i.e. resistant to inhaled corticosteroid doses less than or equal to 200μg fluticasone equivalent) 4. To look for an association between digestive dysbiosis and respiratory dysbiosis 5. To constitute a biocollection (sputum, stool, blood) of children with asthma for future analysis 30 patients are expected to be included in two arms : 15 uncontrolled asthmatic patients at moderate doses of inhaled corticosteroids and 15 asthmatic patients controlled at mild to moderate doses of inhaled corticosteroids. Inclusion period : 12 months. Duration of patient's participation: 6 years Total study duration: 7 years ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05192499
Study type Interventional
Source University Hospital, Brest
Contact Pierrick CROS
Phone 02 98 22 36 59
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date February 1, 2022
Completion date February 1, 2028

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04896502 - Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers N/A
Active, not recruiting NCT03503812 - Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches N/A
Not yet recruiting NCT04656587 - BPAP in Pediatric Asthma Pilot Study N/A
Not yet recruiting NCT04918394 - Mold Exposure and Impact on Asthma Control in French Asthmatic Children
Completed NCT04388098 - Oral Health Status of Asthmatic Children
Terminated NCT03586544 - Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity Phase 4
Recruiting NCT04821908 - Consequences of COVID 19 Pandemic on Childhood Asthma
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Recruiting NCT04908384 - Improving Asthma Care Together (IMPACT): A Shared Management Pilot Study N/A
Recruiting NCT04166344 - A mHealth Intervention to Improve Symptom Control in Children and Adolescents With Difficult-to-control Asthma N/A
Not yet recruiting NCT04942639 - Evaluation of Efficacy and Tolerance of JOE on 4 to 11 Years Old Asthmatic Patients of GINA Grade 2,3 or 4. Phase 3
Active, not recruiting NCT03907410 - The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial N/A
Completed NCT03967873 - Child Asthma : What Parents Attitude During an Asthma Attack at Home Before Consulting the Pediatric Emergencies
Completed NCT04874649 - Balloon Blowing Breathing Exercise in School-age Children With Asthma. N/A
Recruiting NCT04527016 - Airway Microbiota Based Treatment of Asthma in Preschool Children Phase 4
Not yet recruiting NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT04873193 - Safety and Feasibility of a Novel Device for Assessing Respiratory Function in Children N/A
Recruiting NCT03645889 - Traditional Chinese Medicine in Management of Childhood Asthma Phase 2
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Completed NCT04289714 - Novel Electronic Monitoring Devices (NEMD) to Monitor Adherence in Children With Asthma N/A